Medicover and LUX MED: The Rivals Who Are Not InsurersThin moat

The most interesting competitive front at PZU is one where the opponents do not sell insurance. PZU Zdrowie, the health arm the company is counting on for growth, competes against LUX MED and Medicover — two private medical operators, both controlled by Western capital, both of which got there first.

The scale gap is real. LUX MED's revenue from medical services reached about 4,7 billion złoty in 2024, up from 4 billion the year before, on a network of more than 300 centres¹. Medicover's group revenue grew 17,1 percent in the second quarter of 2025 to 596,7 million euros with operating profit nearly doubling, driven substantially by Poland². PZU Zdrowie's revenue rose about 14 percent to roughly 2,2 billion złoty against a target above 3 billion by 2027. PZU is third in a business whose leaders have been assembling clinics for two decades.

What makes this contest different from every other page here is what is actually scarce. Insurers compete for premium; these three compete for doctors, for appointment slots, for clinic sites in the right districts. A price advantage is worth nothing if the patient cannot get seen in a fortnight, and no actuarial model produces a cardiologist.

The overlap with PZU's core is the part worth sitting with. LUX MED's client base was about 59 percent corporate in 2024 — subscriptions sold to employers. Those are the same employers whose group life contracts anchor PZU's stickiest insurance franchise. Two companies with no insurance licence are calling on PZU's most valuable customers every year with a product those customers increasingly want.

Watch health revenue against the 2027 target. The moat's own PZU Zdrowie pages argue why owning the provider controls the claim cost; this page is about whether PZU can buy enough of the provider to matter.